Lipoproteins and Cardiovascular Health

Lipoproteins are particles that ferry cholesterol and fats through the bloodstream, and their balance—particularly elevated LDL cholesterol—drives the buildup of plaques inside arterial walls that underlies most heart attacks and strokes. Statins, drugs that inhibit cholesterol synthesis in the liver, have become one of the most studied interventions in medicine, with large clinical trials and meta-analyses establishing their ability to reduce atherosclerotic cardiovascular events across a wide range of patient populations. Researchers are now working to clarify how aggressively LDL should be lowered in different risk groups, why some patients derive unexpectedly large benefits that may reflect anti-inflammatory effects beyond cholesterol reduction—a phenomenon partly tracked through markers like C-reactive protein—and how genetic variation in cholesterol metabolism should guide treatment decisions. Ongoing work also examines newer drug classes that can push LDL far lower than statins alone, raising questions about the limits of benefit and the long-term safety of very low cholesterol levels.

Works

115,674

Total citations

2,146,530

Keywords

Cholesterol-loweringStatinsCardiovascular Disease PreventionLDL CholesterolClinical TrialsAtherosclerotic Cardiovascular Risk